Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 dose-ranging study with peginterferon alfa-2b and ribavirin in genotype 1 chronic hepatitis C
2011-000759-18Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of grazoprevir in hepatitis C virus infection (5 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients achieving undetectable HCV RNA at Week 12. Started Apr 2011; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-000759-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000759-18.